Report calls for better evaluation of pharmcogenetic testsBMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7405.11-a (Published 03 July 2003) Cite this as: BMJ 2003;327:11
- Ray Moynihan
- Washington, DC
The marketing of pharmacogenetic tests may be moving much faster than the underlying medical science, warns a study published this week.
“There is widespread recognition that pharmacogenetics may have been oversold … The basic science is still substantially uncertain,” argues its author, David Melzer, and colleagues from the Department of Public Health and Primary Care at the University of Cambridge. Funded by the Wellcome Trust, the study was based on interviews and focus groups involving key experts on pharmacogenetics and major stakeholders in the United States and …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial